We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-Seed financing totalling to 3.5 million CHF.